Professor Roy Fleischmann, Rheumatologist, University of Texas Southwestern Medical Center at Dallas, TX, US
Can you explain the rationale and aim of SELECT-COMPARE?
Can you describe participant characteristics of note?
Can you describe the study design, including endpoints?
What did the results show?
What’s next for upadacitinib in patients with rheumatoid arthritis?
Upadacitinib shows clinically significant difference in response rate versus adalimumab in active RA
Tocilizumab for the treatment of systemic sclerosis: efficacy and safety results from phase III trial focuSSced
Intra-articular TPX-100 for knee tibiofemoral osteoarthritis: recent data from TPX-100-1
Complete renal response reached earlier with abatacept versus placebo in lupus nephritis
Efficacy and safety profile outcomes of switching from adalimumab to baricitinib: long-term data in patients with rheumatoid arthritis
Faster decline in maternal mortality in SLE patients as compared with non-SLE patients
Did changes in composite indices of disease activity correlate with radiographic progression in the GO-VIBRANT trial of active PsA?
3-year data on secukinumab in ankylosing spondylitis support efficacy and safety profile
Diagnosis of giant-cell arteritis more accurate with PET/CT scan than temporal artery biopsy
Approximately half of RA patients do not have their therapy changed as needed within a year
Top image: © stockdevil
The content and interpretation of these conference highlights are the views and comments of the speakers / authors.
Supported by
